HKSE - Delayed Quote HKD

CStone Pharmaceuticals (2616.HK)

0.860 +0.030 (+3.61%)
At close: 4:09 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
481,072.000
481,363.000
243,718.000
1,038,832.000
Cost of Revenue
218,299.000
202,985.000
106,832.000
241,421.000
Gross Profit
262,773.000
278,378.000
136,886.000
797,411.000
Operating Expense
1,034,874.000
1,181,475.000
1,930,359.000
1,861,832.000
Operating Income
-772,101.000
-903,097.000
-1,793,473.000
-1,064,421.000
Net Non Operating Interest Income Expense
12,084.000
1,195.000
7,561.000
22,841.000
Pretax Income
-750,335.000
-902,678.000
-1,920,100.000
-1,220,999.000
Net Income Common Stockholders
-750,335.000
-902,678.000
-1,920,100.000
-1,220,999.000
Diluted NI Available to Com Stockholders
-750,335.000
-902,678.000
-1,920,100.000
-1,220,999.000
Basic EPS
-0.63
-0.77
-1.65
-1.17
Diluted EPS
-0.63
-0.77
-1.65
-1.17
Basic Average Shares
1,210,571.000
1,172,839.000
1,165,209.000
1,046,032.000
Diluted Average Shares
1,210,571.000
1,172,839.000
1,165,209.000
1,046,032.000
Rent Expense Supplemental
--
3,069.000
2,475.000
3,160.000
Total Expenses
1,253,173.000
1,384,460.000
2,037,191.000
2,103,253.000
Net Income from Continuing & Discontinued Operation
-750,335.000
-902,678.000
-1,920,100.000
-1,220,999.000
Normalized Income
-715,230.000
-840,749.000
-1,854,995.000
-1,223,416.000
Interest Income
23,499.000
9,672.000
9,803.000
24,161.000
Interest Expense
11,415.000
8,477.000
2,242.000
1,320.000
Net Interest Income
12,084.000
1,195.000
7,561.000
22,841.000
EBIT
-738,920.000
-894,201.000
-1,917,858.000
-1,219,679.000
EBITDA
-738,920.000
-849,661.000
-1,895,197.000
-1,204,878.000
Reconciled Cost of Revenue
218,299.000
202,985.000
106,832.000
241,421.000
Reconciled Depreciation
--
44,540.000
22,661.000
14,801.000
Net Income from Continuing Operation Net Minority Interest
-750,335.000
-902,678.000
-1,920,100.000
-1,220,999.000
Total Unusual Items Excluding Goodwill
-35,105.000
-61,929.000
-65,105.000
2,417.000
Total Unusual Items
-35,105.000
-61,929.000
-65,105.000
2,417.000
Normalized EBITDA
-703,815.000
-787,732.000
-1,830,092.000
-1,207,295.000
12/31/2020 - 2/26/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

0690.HK Uni-Bio Science Group Limited
0.086
+3.61%
 
1228.HK CANbridge Pharmaceuticals Inc.
0.475
+48.44%
 
2509.HK Qyuns Therapeutics Co., Ltd.
23.900
+0.21%
 
2696.HK Shanghai Henlius Biotech, Inc.
15.260
0.00%
 
6996.HK Antengene Corporation Limited
0.850
+7.59%
 
2105.HK Laekna, Inc.
6.030
+12.92%
 
2257.HK Sirnaomics Ltd.
5.950
+2.06%
 
1877.HK Shanghai Junshi Biosciences Co., Ltd.
9.650
+3.88%
 
1244.HK 3D Medicines Inc.
5.650
+1.62%
 
1672.HK Ascletis Pharma Inc.
1.270
0.00%